Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

Thx for flagging this. My guess: unaffiliated research tied to the PYMX days of yore - a decade back. The same lead researcher out of Pittsburgh. Kowalski.

See
http://www.businesswire.com/news/home/20061113005507/en/Data-PolyMedixs-Antibiotics-Presented-40th-Annual-Meeting#.VUSxzFJOKnM

http://eyemicrobiology.upmc.com/2006Abstracts/Abstract%203.htm

http://ophthalmology.medicine.pitt.edu/personnelDetail.asp?pid=2372&id=127&ptype=2&pnavcat=2

I've forwarded to CTIX in case it's not on their radar. The attribution currently is tied to PolyMedix not Cellceutix, which makes me think they're not---maybe both parties... Ie folks not knowing CTIX acquired the IP portfolio -- and a few chairs -- post bankruptcy.

While Brilacidin was unable to penetrate wall, per the new abstract, the earlier 06 data had them testing other HDP-Ms (pmx30006, pmx30016, pmx70004). So perhaps other compounds could be "tweaked" (I know, that dreaded word) for greater efficacy. Welcome any docs/expert opinions.